Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 48

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 3
Chunk 48
---
                                        
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (8)      Consists of 8,250 ordinary shares issuable upon exercise of options that are currently exercisable or exercisable within 60 days               
           of March 17, 2025, of which options to purchase the following number of shares expire on the following dates, respectively: 1,000 on December  
           23, 2028, 250 on February 1, 2030, 250 on February 1, 2031, 1,800 on August 10, 2031, 1,800 on September 15, 2032, 1,800 on May 11, 2033       
           and 1,350 on June 13, 2034. The weighted average exercise price of these options is $16.15 per ordinary share.                                 
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (9)      Includes 83,886 ordinary shares held by Mr. Recanati. Also includes 8,437 ordinary shares issuable upon exercise of options that         
           are currently exercisable or exercisable within 60 days of March 17, 2025, of which options to purchase the following number of shares   
           expire on the following dates, respectively: 250 on July 2, 2025, 250 on May 18, 2026, 250 on May 16, 2027, 250 on June 25, 2028, 250    
           on July 30, 2029, 250 on November 17, 2030, 187 on June 11, 2031, 1,800 on September 1, 2031, 1,800 on September 15, 2032, 1,800 on May  
           11, 2033 and 1,350 on June 13, 2034. The weighted average exercise price of these options is NIS 71.28 per ordinary share.               
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (10)      Consists of 8,250 ordinary shares issuable upon exercise of options that are currently exercisable or exercisable within 60 days               
            of March 17, 202